269 related articles for article (PubMed ID: 33229322)
1. [Progress on the molecular mechanisms of PCSK9-mediated degradation of low density lipoprotein receptor].
Wu YX; Wang Y
Yi Chuan; 2020 Oct; 42(10):965-978. PubMed ID: 33229322
[TBL] [Abstract][Full Text] [Related]
2. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
3. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Guo S; Xia XD; Gu HM; Zhang DW
Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
[TBL] [Abstract][Full Text] [Related]
4. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
5. The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.
Susan-Resiga D; Girard E; Kiss RS; Essalmani R; Hamelin J; Asselin MC; Awan Z; Butkinaree C; Fleury A; Soldera A; Dory YL; Baass A; Seidah NG
J Biol Chem; 2017 Feb; 292(5):1573-1590. PubMed ID: 27998977
[TBL] [Abstract][Full Text] [Related]
6. Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C).
Ben-Naim L; Khalaila I; Papo N
Protein Eng Des Sel; 2022 Feb; 35():. PubMed ID: 35174858
[TBL] [Abstract][Full Text] [Related]
7. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
8. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
Pedro-Botet J; Badimón L
Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
[TBL] [Abstract][Full Text] [Related]
9. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
[TBL] [Abstract][Full Text] [Related]
10. APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.
Fu T; Guan Y; Xu J; Wang Y
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):883-889. PubMed ID: 28495363
[TBL] [Abstract][Full Text] [Related]
11. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
[TBL] [Abstract][Full Text] [Related]
12. PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
Huang M; Zhao Z; Cao Q; You X; Wei S; Zhao J; Bai M; Chen Y
Metabolism; 2019 May; 94():88-95. PubMed ID: 30831144
[TBL] [Abstract][Full Text] [Related]
13. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
[TBL] [Abstract][Full Text] [Related]
14. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
[TBL] [Abstract][Full Text] [Related]
15. Modulation of vascular endothelial inflammatory response by proprotein convertase subtilisin-kexin type 9.
Leung AKK; Xue YC; de Guzman A; Grzelkovski G; Kong HJ; Genga KR; Russell JA; Boyd JH; Francis GA; Walley KR
Atherosclerosis; 2022 Dec; 362():29-37. PubMed ID: 36207148
[TBL] [Abstract][Full Text] [Related]
16. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
[TBL] [Abstract][Full Text] [Related]
17. Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression.
Wang J; Wang YS; Huang YP; Jiang CH; Gao M; Zheng X; Yin ZQ; Zhang J
Phytomedicine; 2021 Oct; 91():153688. PubMed ID: 34380071
[TBL] [Abstract][Full Text] [Related]
18. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.
Holla ØL; Cameron J; Berge KE; Ranheim T; Leren TP
BMC Cell Biol; 2007 Mar; 8():9. PubMed ID: 17328821
[TBL] [Abstract][Full Text] [Related]
19. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
[TBL] [Abstract][Full Text] [Related]
20. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]